CRISPR, Vertex Pharmaceuticals

‘Much-needed hope’ as CRISPR gene editing therapy recommended for sickle cell disease
Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant access to gene-editing therapy on the NHS. View on euronews
Vertex wins reimbursement deal for CRISPR-partnered sickle cell therapy in England
Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday a reimbursement agreement with England’s National Health Service (NHS) to allow patients with sickle cell disease (SCD) to access its gene-edited therapy Casgevy,
Vertex, U.K. reach reimbursement deal for CRISPR-based medicine for sickle cell disease
People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the U.K. and Vertex.
Breakthrough in gene-editing with Cas12a for modeling human diseases
Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.
NHS to offer 'groundbreaking' sickle cell gene therapy
The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts say.
UK health system to offer cutting-edge gene therapy for sickle cell disease
Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the National Institute for Health and Care Excellence (NICE) said on Friday.
Revolutionary gene-editing therapy for sickle cell approved
NHS Karla Sofia Gascón apologizes for old tweets, says she is 'deeply sorry to those I have caused pain' Everything we know about China's new 6th gen fighter jet... AstraZeneca cancels £450m investmen
STAT21h
Pharmalittle: We’re reading about FDA OK for Vertex non-opioid pain drug, vaccine advisory committee, and more
Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way for the rollout of a product that has simultaneously sparked high hopes and ...
Defeating Superbugs: Researchers Uncover New Weapon Against Antibiotic Resistance
Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...
MIT Technology Review3d
Mice with two dads have been created using CRISPR
It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.
ZME Science on MSN2d
Scientists Create Mice with Two Fathers in a Genetic Breakthrough That Could Save Endangered Species
Researchers use CRISPR to overcome seemingly insurmontable reproductive barriers — but that doesn't mean this could work for ...
Crispr Therapeutics price target lowered to $30 from $45 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...
MIT Technology Review2d
The Download: mice with two dads, and Meta’s fact-checking challenges
Once a week, Sun Kai has a video call with his mother, and they discuss his day-to-day life. But Sun’s mother died five years ...
News Medical4d
CRISPR-Based Diagnostics: The Future of Disease Detection
CRISPR technology has revolutionized genetic testing and disease detection, offering precise, rapid, and cost-effective diagnostic solutions. This gene-editing tool has been adapted for molecular ...
CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...
Jim Cramer Says “CRISPR (CRSP) Keeps Losing Money Like Moderna” – Here’s Why
We recently published a list of 9 Stocks Jim Cramer Talked About. In this article, we are going to take a look at where ...